The ACCORD-Lipid study: Implications for treatment of dyslipidemia in Type 2 diabetes mellitus

Clinical Lipidology

Volumn 6, Issue 1, 2011, Pages 9-20

  Elam, Marshall ^c   Lovato, Laura ^a   Ginsberg, Henry ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c NONE

Author keywords

coronary heart disease; diabetes; dyslipidemia; fenofbrate; HDL C; simvastatin; stroke; triglyceride

Indexed keywords

BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; GEMFIBROZIL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; GALLBLADDER DISEASE; GLYCEMIC CONTROL; HEART INFARCTION; HEPATITIS; HIGH RISK POPULATION; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LEG AMPUTATION; MULTICENTER STUDY (TOPIC); MYALGIA; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; SEX DIFFERENCE; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79951487649     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.84     Document Type: Article

References (54)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229-234 (1998). (Pubitemid 28350165)
2. Grundy SM, Cleeman JI, Merz CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227-239 (2004). (Pubitemid 38924592)
3. Buse JB, Bigger JT, Byington RP et al.: Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am. J. Cardiol. 99, 21I-33I (2007).
4. Ginsberg HN, Elam MB, Lovato LC et al.: Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010).
5. Cushman WC, Evans GW, Byington RP et al.: Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575-1585 (2010).
6. Gerstein HC, Miller ME, Byington RP et al.: Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008). (Pubitemid 351831356)
7. Almdal T, Scharling H, Jensen JS, Vestergaard H: The independent effect of Type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch. Intern. Med. 164, 1422-1426 (2004). (Pubitemid 38937853)
8. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16, 434-444 (1993). (Pubitemid 23046633)
9. Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361, 2005-2016 (2003).
10. Shepherd J, Barter P, Carmena R et al.: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29, 1220-1226 (2006). (Pubitemid 44125913)
11. Colhoun HM, Betteridge DJ, Durrington PN et al.: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685-696 (2004). (Pubitemid 39140624)
12. Rubins HB, Robins SJ, Collins D et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med. 162, 2597-2604 (2002). (Pubitemid 35453499)
13. Chahil TJ, Ginsberg HN: Diabetic dyslipidemia. Endocrinol. Metab. Clin. North Am. 35, 491-510, VII-VIII (2006).
14. Turner RC, Millns H, Neil HA et al.: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316, 823-828 (1998). (Pubitemid 28112428)
15. Grundy SM, Vega GL, Yuan Z, Battisti W P, Brady WE, Palmisano J: Effectiveness and tolerability of simvastatin plus fenofbrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol. 95, 462-468 (2005). (Pubitemid 40247539)
16. Genest J, McPherson R, Frohlich J et al.: 2009 Canadian Cardiovascular Society/ Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult -2009 recommendations. Can. J. Cardiol. 25, 567-579 (2009).
17. Home P, Mant J, Diaz J, Turner C: Management of Type 2 diabetes: summary of updated NICE guidance. BMJ 336, 1306-1308 (2008). (Pubitemid 351839637)
18. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 106, 1024-1028 (2002). (Pubitemid 34925341)
19. Ballantyne CM, Corsini A, Davidson MH et al.: Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. 163, 553-564 (2003). (Pubitemid 36314342)
20. Ginsberg HN, Bonds DE, Lovato LC et al.: Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am. J. Cardiol. 99, 56I-67I (2007).
21. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
22. Graham DJ, Staffa JA, Shatin D et al.: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292, 2585-2590 (2004). (Pubitemid 39577514)
23. Chang JT, Staffa JA, Parks M, Green L: Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfbrozil combination therapy. Pharmacoepidemiol. Drug Saf. 13, 417-426 (2004). (Pubitemid 38996852)
24. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH: Effects of fbrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. 30, 1280-1287 (2002). (Pubitemid 35265837)
25. Corsini A, Bellosta S, Davidson MH: Pharmacokinetic interactions between statins and fbrates. Am. J. Cardiol. 96, 44K-49K; discussion 34K-35K (2005).
26. Bergman AJ, Murphy G, Burke J et al.: Simvastatin does not have a clinically signifcant pharmacokinetic interaction with fenofbrate in humans. J. Clin. Pharmacol. 44, 1054-1062 (2004). (Pubitemid 39096820)
27. Jones PH, Davidson MH: Reporting rate of rhabdomyolysis with fenofbrate + statin versus gemfbrozil + any statin. Am. J. Cardiol. 95, 120-122 (2005). (Pubitemid 40051126)
28. Keech A, Simes RJ, Barter P et al.: Effects of long-term fenofbrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
29. Lipscombe J, Lewis GF, Cattran D, Bargman JM: Deterioration in renal function associated with fbrate therapy. Clin. Nephrol. 55, 39-44 (2001). (Pubitemid 32041781)
30. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A: Fenofbrate increases creatininemia by increasing metabolic production of creatinine. Nephron 92, 536-541 (2002).
31. Forsblom C, Hiukka A, Leinonen ES, Sundvall J, Groop PH, Taskinen MR: Effects of long-term fenofbrate treatment on markers of renal function in Type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care 33, 215-220 (2010).
32. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G: Fenofbrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in Type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis. 45, 485-493 (2005). (Pubitemid 40341327)
33. Westphal S, Dierkes J, Luley C: Effects of fenofbrate and gemfbrozil on plasma homocysteine. Lancet 358, 39-40 (2001). (Pubitemid 32709742)
34. Genest J, Frohlich J, Steiner G: Effect of fenofbrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in Type 2 diabetes mellitus. Am. J. Cardiol. 93, 848-853 (2004). (Pubitemid 38429595)
35. Taskinen MR, Sullivan DR, Ehnholm C et al.: Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofbrate. Arterioscler. Thromb. Vasc. Biol. 29, 950-955 (2009).
36. Clofbrate and niacin in coronary heart disease. JAMA 231, 360-381 (1975)
37. A co-operative trial in the primary prevention of ischaemic heart disease using clofbrate. Report from the Committee of Principal Investigators. Br. Heart J. 40, 1069-1118 (1978).
38. Frick MH, Elo O, Haapa K et al.: Helsinki Heart Study: primary-prevention trial with gemfbrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237-1245 (1987). (Pubitemid 17147964)
39. Rubins HB, Robins SJ, Collins D et al.: Gemfbrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410-418 (1999). (Pubitemid 29362514)
40. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafbrate Infarction Prevention (BIP) study. Circulation 102, 21-27 (2000).
41. Manninen V, Elo MO, Frick MH et al.: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260, 641-651 (1988).
42. Tenkanen L, Manttari M, Manninen V: Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfbrozil. Experience from the Helsinki Heart Study. Circulation 92, 1779-1785 (1995).
43. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15, 820-825 (1992).
44. Robins SJ, Collins D, Wittes JT et al.: Relation of gemfbrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285, 1585-1591 (2001). (Pubitemid 32240250)
45. Robins SJ, Rubins HB, Faas FH et al.: Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 26, 1513-1517 (2003). (Pubitemid 36929188)
46. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafbrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med. 165, 1154-1160 (2005). (Pubitemid 40720740)
47. Robins SJ, Bloomfeld HE: Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr. Opin. Lipidol. 17, 431-439 (2006). (Pubitemid 44079482)
48. Elkeles RS, Diamond JR, Poulter C et al.: Cardiovascular outcomes in Type 2 diabetes. A double-blind placebo-controlled study of bezafbrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 21, 641-648 (1998). (Pubitemid 28172949)
49. Scott R, O'Brien R, Fulcher G et al.: Effects of fenofbrate treatment on cardiovascular disease risk in 9,795 individuals with Type 2 diabetes and various components of the metabolic syndrome: the Fenofbrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32, 493-498 (2009).
50. Keech AC, Mitchell P, Summanen PA et al.: Effect of fenofbrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370, 1687-1697 (2007). (Pubitemid 350100775)
51. Chew EY, Ambrosius WT, Davis MD et al.: Effects of medical therapies on retinopathy progression in Type 2 diabetes. N. Engl. J. Med. 363, 233-244 (2010).
52. Rajamani K, Colman PG, Li LP et al.: Effect of fenofbrate on amputation events in people with Type 2 diabetes mellitus (FIELD study): a prespecifed analysis of a randomised controlled trial. Lancet 373, 1780-1788 (2009).
53. Sever PS, Poulter NR, Dahlof B et al.: Reduction in cardiovascular events with atorvastatin in 2,532 patients with Type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial -lipid-lowering arm (ASCOT-LLA). Diabetes Care 28, 1151-1157 (2005). (Pubitemid 40616627)
54. Elam MB, Lovato LC, Byington RP et al.: Abstract 19724: hypertriglyceridemia and low HDL-C predicts fenofbrate response in the ACCORD-Lipid trial. Circulation 122, A19724 (2010).